Methotrexate tablets

Tetrahydrofolate is an important coenzyme for synthesizing purine nucleotides and pyrimidine deoxynucleotides in the body. As a folate reductase inhibitor, this product mainly inhibits dihydrofolate reductase and prevents dihydrofolate from being reduced to physiologically active tetrahydrofolate, thereby hindering the transfer of one-carbon groups in the biosynthesis of purine nucleotides and pyrimidine nucleotides, resulting in the inhibition of DNA biosynthesis. In addition, this product also has an inhibitory effect on thymic nucleotide synthetase, but its effect on inhibiting RNA and protein synthesis is weaker. This product mainly acts on the S phase of the cell cycle and is a cell cycle-specific drug. It also has a delaying effect on cells in the G1S phase, but has a weaker effect on cells in the G1 phase.

Methotrexate.

This product is light orange-yellow tablets.

1. All types of acute leukemia, especially acute lymphocytic leukemia, malignant lymphoma, non-Hodgkin's lymphoma, mycosis fungoides, and multiple myelopathy; 2. Head and neck cancer, lung cancer, various soft tissue sarcomas, and psoriasis; 3. Breast cancer, ovarian cancer, cervical cancer, malignant hydatidiform mole, choriocarcinoma, and testicular cancer.

For adults, take 5mg to 10mg (2-4 tablets) orally, once a day, 1 to 2 times a week, and the safe dose for a course of treatment is 50mg to 100mg (20 to 40 tablets). For maintenance treatment of acute lymphoblastic leukemia, take 15mg to 20mg/m2 (6 to 8 tablets/m2) once a week.

1. Gastrointestinal reactions, including stomatitis, lip ulcers, pharyngitis, nausea, vomiting, abdominal pain, diarrhea, and gastrointestinal bleeding. Anorexia is common, and pseudomembranous or hemorrhagic enteritis is occasionally seen; 2. Liver function damage, including jaundice, increased alanine aminotransferase, alkaline phosphatase, γ-glutamyl transpeptidase, etc. Long-term oral administration can lead to liver cell necrosis, fatty liver, fibrosis and even cirrhosis; 3. When used in large doses, due to the deposition of this product and its metabolites in the renal tubules, hyperuricemia nephropathy may occur. At this time, hematuria, proteinuria, oliguria, azotemia or even uremia may occur; 4. Long-term use of the drug can cause cough, shortness of breath, pneumonia or pulmonary fibrosis; 5. Bone marrow suppression: mainly leukopenia and thrombocytopenia. Long-term oral administration of small doses can lead to significant bone marrow suppression, anemia and thrombocytopenia

Patients with known hypersensitivity to this product are contraindicated.

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: Because this product has teratogenic effects and is excreted from breast milk, pregnancy and lactation are prohibited during medication. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.

1. Ethanol and other drugs that are harmful to the liver, if used together with this product, can increase liver toxicity; 2. Since this product can cause an increase in the level of uric acid in the blood, patients with gout or hyperuricemia should increase the dose of allopurinol and other drugs accordingly; 3. This product can increase the anticoagulant effect and even cause a lack of hepatic coagulation factors or (and) thrombocytopenia, so it should be used with caution with other anticoagulants; 4. When used together with phenylbutazone and sulfonamides, the competition with protein binding may cause an increase in the serum concentration of this product, leading to toxic reactions. 5. Oral kanamycin can increase the absorption of oral this product, while oral neomycin sodium can reduce its absorption; 6. When used together with weak organic acids and salicylates, it can inhibit the renal excretion of this product and lead to increased serum drug concentration, which in turn increases toxicity. The dosage should be reduced as appropriate; 7. Drugs such as triamterene and pyrimethamine have anti-folate effects. If used together with this product, their toxic side effects may be increased; 8. When used together with fluorouracil, or when fluorouracil is used first and then this product, an antagonistic effect may be produced. If this product is used first and then fluorouracil is used 4 to 6 hours later, a synergistic effect may be produced. The combination of this product and L-asparaginase may also lead to reduced efficacy. If this product is used 10 days after the latter, or L-asparaginase is given within 24 hours after the use of this product, the efficacy can be enhanced and the toxic side effects on the gastrointestinal tract and bone marrow can be reduced. It has been reported that the use of cytarabine 24 hours before or 10 minutes after the use of this product can increase the anticancer activity of this product. Caution should be exercised when this product is used concurrently with radiotherapy or other bone marrow suppressive drugs.

Keep away from light and store in sealed container.

2.5mg

36 months.

Hunan Zhengqing Pharmaceutical Co., Ltd.

• Founded in:

  1994-06-22

• Address:

  No. 7, Fortune Road, Huaihua High-tech Industrial Development Zone, Hunan

• Tax NO.:

  91431200183808108W

• Registered Funds:

  204.270346 million yuan

• Website:

  Log in to view

• Email:

  Log in to view